Table 3

Results of cost-effectiveness analysis

Intensive control treatment strategiesCost of medicationsTotal costsIncremental costsQALYsIncremental QALYsIncremental cost-effectiveness ratio*Cost-effectiveness ratio, relative to glyburide strategy
Glyburide as second-line therapy$65,205$146,95015.2143
Sitagliptin as second-line therapy$85,418$4,167,163$20,21315.33350.1192$169,572$169,572
Exenatide as second-line therapy$89,054$170,799$3,63615.2998−0.0337Dominated$278,935
  • *Changes in costs in $ and QALYs were calculated relative to the next most expensive treatment strategy.